Telix Pharma hits record high, partners with S.Korean firm for cancer imaging product
03/12/2020 24:32
** Shares of Telix Pharmaceuticals TLX.AX rise as much as
8.3% to record high of A$4.33
** Telix on Wednesday ending at a record high of A$4.0 after
co received official nod for a cancer therapy study urn:newsml:reuters.com:*:nL4N2II07F
** On Thursday, TLX announces partnership with South Korean
radiopharmaceutical firm DuChemBio Co (https://bit.ly/39D6AIm)
** Agreement grants DuChemBio exclusive rights to
commercialize TLX's prostate cancer imaging product in South
Korea
** TLX on track for a fifth consecutive session of gains
** Stock among top 10 biggest percentage gainer in the ASX
All Ordinaries index .AORD
** Telix stock up 158% this year, as of last close, compared
with a small gain in the ASX All Ordinaries index
(Reporting by Sameer Manekar in Bengaluru)
((Sameer.Manekar@thomsonreuters.com;))